Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

654 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters.
Parisi S, Ruggeri L, Dan E, Rizzi S, Sinigaglia B, Ocadlikova D, Bontadini A, Giudice V, Urbani E, Ciardelli S, Sartor C, Cristiano G, Nanni J, Zannoni L, Chirumbolo G, Arpinati M, Lewis RE, Bonifazi F, Marconi G, Martinelli G, Papayannidis C, Paolini S, Velardi A, Cavo M, Lemoli RM, Curti A. Parisi S, et al. Front Immunol. 2022 Jan 31;12:804988. doi: 10.3389/fimmu.2021.804988. eCollection 2021. Front Immunol. 2022. PMID: 35173709 Free PMC article.
Patient with ataxia telangiectasia who developed acute myeloid leukemia.
Brioli A, Parisi S, Iacobucci I, Cavo M, Papayannidis C, Anna Zannetti B, Martinelli G, Baccarani M. Brioli A, et al. Among authors: parisi s. Leuk Lymphoma. 2011 Sep;52(9):1818-20. doi: 10.3109/10428194.2011.577256. Epub 2011 Jun 10. Leuk Lymphoma. 2011. PMID: 21657959 No abstract available.
Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients.
Curti A, Ruggeri L, D'Addio A, Bontadini A, Dan E, Motta MR, Trabanelli S, Giudice V, Urbani E, Martinelli G, Paolini S, Fruet F, Isidori A, Parisi S, Bandini G, Baccarani M, Velardi A, Lemoli RM. Curti A, et al. Among authors: parisi s. Blood. 2011 Sep 22;118(12):3273-9. doi: 10.1182/blood-2011-01-329508. Epub 2011 Jul 25. Blood. 2011. PMID: 21791425 Free article. Clinical Trial.
Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin.
Iacobucci I, Lonetti A, Candoni A, Sazzini M, Papayannidis C, Formica S, Ottaviani E, Ferrari A, Michelutti A, Simeone E, Astolfi A, Abbenante MC, Parisi S, Cattina F, Malagola M, Russo D, Damiani D, Gherlinzoni F, Gottardi M, Baccarani M, Fanin R, Martinelli G. Iacobucci I, et al. Among authors: parisi s. Pharmacogenomics J. 2013 Aug;13(4):335-41. doi: 10.1038/tpj.2012.13. Epub 2012 May 15. Pharmacogenomics J. 2013. PMID: 22584460
Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response.
Iacobucci I, Lonetti A, Venturi C, Ferrari A, Papayannidis C, Ottaviani E, Abbenante MC, Paolini S, Bresciani P, Potenza L, Parisi S, Cattina F, Soverini S, Russo D, Luppi M, Martinelli G. Iacobucci I, et al. Among authors: parisi s. Leuk Res. 2014 May;38(5):581-5. doi: 10.1016/j.leukres.2014.02.005. Epub 2014 Feb 18. Leuk Res. 2014. PMID: 24630366
Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients.
Zuffa E, Franchini E, Papayannidis C, Baldazzi C, Simonetti G, Testoni N, Abbenante MC, Paolini S, Sartor C, Parisi S, Marconi G, Cattina F, Bochicchio MT, Venturi C, Ottaviani E, Cavo M, Martinelli G. Zuffa E, et al. Among authors: parisi s. Oncotarget. 2015 Oct 13;6(31):31284-94. doi: 10.18632/oncotarget.5161. Oncotarget. 2015. PMID: 26384303 Free PMC article.
654 results